Last reviewed · How we verify
Aminobutene (DIMETHYLTHIAMBUTENE)
Aminobutene (generic name: DIMETHYLTHIAMBUTENE) is a drug. It is currently in Phase 2 development.
Aminobutene is thought to work by interacting with specific biological pathways, but the exact mechanism is unknown.
Aminobutene, also known as DIMETHYLTHIAMBUTENE, is a small molecule compound with unknown target and drug class. Its commercial status and approved indications are unclear. As a small molecule, it is likely to interact with specific biological pathways, but the exact mechanism is unknown. Further research is needed to determine its potential therapeutic applications and safety profile. Its development and ownership history are also unclear.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DIMETHYLTHIAMBUTENE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like a complex orchestra. Aminobutene is like a new instrument that's being introduced, but we don't know exactly how it will fit in or what notes it will play. It's likely to affect the way cells communicate with each other, but we need more research to understand how.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aminobutene CI brief — competitive landscape report
- Aminobutene updates RSS · CI watch RSS
Frequently asked questions about Aminobutene
What is Aminobutene?
How does Aminobutene work?
What is the generic name of Aminobutene?
What development phase is Aminobutene in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing